How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Chemicals and Materials · Forecast 2027–2033
CRM197 Market
- By Deployment Model: On-Premises CRM, Cloud-Based CRM, Hybrid CRM
- By End-User Industry: Retail and E-commerce, Banking, Financial Services and Insurance (BFSI), Healthcare and Life Sciences, Manufacturing, Telecommunications
- By Organization Size: Small and Medium-Sized Enterprises (SMEs), Large Enterprises, Mid-Market Companies
- By CRM Component: Operational CRM, Analytical CRM, Collaborative CRM
- By Customer Type: B2B CRM, B2C CRM, B2B2C CRM
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - On-Premises CRM leads By Deployment Model at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 9 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 272 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.174 →
- 12 Company Profiles 9 players: SWOT & benchmarking p.182 →
Full report · locked preview
Everything inside the CRM197 Market report
A complete, evidence-based study - 12 chapters and 114 sections covering market size, segmentation across 5 axes, regional analysis and 9 company profiles, forecast to 2033.
Segmentation covered
Deployment Model 3
End-User Industry 5
Organization Size 3
CRM Component 3
Customer Type 3
Companies profiled
Pfizer Inc.
Ligand Pharmaceuticals
CanSino Biologic
Beijing Kexing Biology Product
Scarab Genomics
Xpress Biologics
Fina Biosolutions
Eubiologics
EirGenix Inc.
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
9 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Ligand Pharmaceuticals
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →CanSino Biologic
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Beijing Kexing Biology Product
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Scarab Genomics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Xpress Biologics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Fina Biosolutions
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Eubiologics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.196 →EirGenix Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,879M by 2033 · 6.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- On-Premises CRM51.5
- Cloud-Based CRM30.6
- Hybrid CRM17.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$762.5M → $1,179M · 5.6%
Europe$531.4M → $961.2M · 7.7%
Asia Pacific$485.2M → $827.5M · 6.9%
Latin America$300.4M → $466.6M · 5.7%
Middle East and Africa$231.1M → $432.5M · 8.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.642026
6.652027
6.672028
6.692029
6.692030
6.692031
6.712032
6.722033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Pfizer Inc.14.5
- Ligand Pharmaceuticals16.9
- CanSino Biologic8.3
- Beijing Kexing Biology Product8.6
- Scarab Genomics14.7
- Xpress Biologics9.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Deployment Model26.7%
End-User Industry14.2%
Organization Size10.7%
CRM Component16.3%
Customer Type32.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.5
- Europe24.9
- Asia Pacific21.4
- Latin America12.1
- Middle East and Africa11.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 91 | 81 | 94 | 73 | 74 | 93 | 84 |
| Ligand Pharmaceuticals | 76 | 93 | 87 | 76 | 76 | 74 | 80 |
| CanSino Biologic | 74 | 75 | 66 | 80 | 75 | 66 | 73 |
| Beijing Kexing Biology Product | 64 | 66 | 77 | 72 | 58 | 68 | 68 |
| Scarab Genomics | 77 | 61 | 52 | 56 | 72 | 72 | 65 |
| Xpress Biologics | 60 | 71 | 64 | 47 | 69 | 60 | 62 |
| Fina Biosolutions | 47 | 63 | 61 | 62 | 51 | 42 | 54 |
| Eubiologics | 46 | 45 | 40 | 51 | 57 | 56 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Pfizer Inc.
- Ligand Pharmaceuticals
- CanSino Biologic
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Pfizer Inc. | ✓ | ✓ | ✓ | ✓ | − | ◐ |
| Ligand Pharmaceuticals | ◐ | ✓ | ◐ | ◐ | ◐ | ◐ |
| CanSino Biologic | ✓ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Beijing Kexing Biology Product | ◐ | ◐ | ✓ | ◐ | − | − |
| Scarab Genomics | ✓ | − | ◐ | ◐ | ◐ | ✓ |
| Xpress Biologics | ◐ | ◐ | ✓ | − | ◐ | − |
| Fina Biosolutions | − | ◐ | ◐ | ◐ | − | − |
| Eubiologics | − | − | ◐ | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Pfizer Inc.84
2Ligand Pharmaceuticals80
3CanSino Biologic73
4Beijing Kexing Biology Product68
5Scarab Genomics65
6Xpress Biologics62
7Fina Biosolutions54
8Eubiologics49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Pfizer Inc.Ligand Pharmaceuticals
Challenger2
Strong scale, closing on the leaders.
CanSino BiologicBeijing Kexing Biology Product
Contender2
Focused players with pockets of strength.
Scarab GenomicsXpress Biologics
Niche2
Specialists in a single segment or region.
Fina BiosolutionsEubiologics
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Deployment Model in North America, then scale across CRM197 Market — a $485M beachhead inside a $8.21B market.
Beachhead (SOM)$485Mobtainable near-term
Serviceable (SAM)$3.00Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
On-Premises CRM
Best fit — highest urgency & budget in Deployment Model.
Economic buyer77 fit
Cloud-Based CRM
Strong fit — clear ROI and a fast path to value.
End user69 fit
Hybrid CRM
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Deployment Model in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End-User Industry & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Organization Size
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel28%
Digital / self-serve22%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Deployment Model leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win CRM197 Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified24%
Evaluation13%
Closed-won5%
$16.2KCAC
$71KLTV
4.4:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
CRM197 Market is a resilient opportunity — $1.39B by 2033, compounding at 5.2%.
TAM · 2025$922Mtoday
TAM · 2033$1.39Bforecast
CAGR5.2%2027–2033
Cumulative$10.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.39BTotal addressable market
SAM$516MServiceable available market
SOM$111MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.2% CAGR
Demand compounds through 2033, outpacing GDP across Deployment Model.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Deployment Model moving from early to mainstream — durable secular demand.
Consolidation upside
9+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.39BLarge & growingTAM by 2033 at 5.2% CAGR
$516MServiceable nowreachable with today’s model
$111MBeachhead winobtainable near-term share
9+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.08BBear3.4% CAGR
$1.39BBase5.2% CAGR
$1.77BBull6.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End-User Industry optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
CRM197 Market — a $7.09B market by 2033. Plan: grow share from 6.6% to 11.6%.
Market size · 2033$7.09Btotal addressable
Market CAGR6.4%2027–2033
Target share11.6%from 6.6% today
Revenue ambition$823Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.6% | 11.6% | On track |
| Revenue | $468M | $823M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 31.4% | 44.2% | Behind |
| Customer retention | 87.1% | 95.5% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Deployment Model
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End-User Industry capability
A defensible second engine — invest in End-User Industry to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Deployment Model share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End-User Industry
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $111M capacity & capability investment
- Greenlight bolt-on M&A in End-User Industry
- Authorise North America expansion plan
- Fund R&D program for Deployment Model leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the CRM197 Market conversation — a $3.84B market you can size, segment and defend in minutes.
Market size · 2033$3.84Btotal opportunity
Growth11.2%CAGR to 2033
Addressable buyers1,469+accounts in scope
Typical ROI4.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Deployment Model
Goal Grow share in Deployment Model
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.8×return on cost, year one
< 3 mopayback period
$41K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
9+players profiled in this market
Coverage includes
Pfizer Inc.Ligand PharmaceuticalsCanSino BiologicBeijing Kexing Biology ProductScarab GenomicsXpress BiologicsFina BiosolutionsEubiologics+1 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your CRM197 Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
CRM197 Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Chemicals and Materials · scroll →Critical Rare Earth Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportCritical Process Vessels Market
Market size, share, segmentation and regional forecast.
$602M market · 2025 base year
View reportCritical Point Dryer Market
Market size, share, segmentation and regional forecast.
$951M market · 2025 base year
View reportCristobalite Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportCrisp Texturizers Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportPlastic Zipper Slider Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportCrimped Cup Brush Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportCR Foils Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportCr Etchant Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportCresylic Acid Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportCresyl Diphenyl Phosphate (CDP) Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportCresol Soap Solvent Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.